Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.
Article
CAS
PubMed
Google Scholar
McKeith I, Mintzer J, Aarsland D, Burn D, et al: Dementia with Lewy bodies. Lancet Neurol. 2004, 3: 19-28. 10.1016/S1474-4422(03)00619-7.
Article
PubMed
Google Scholar
Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, et al: Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003, 74: 720-724. 10.1136/jnnp.74.6.720.
Article
PubMed Central
CAS
PubMed
Google Scholar
Farlow M: Alzheimer's disease. Continuum. 2007, 13: 39-68.
Google Scholar
Dekosky ST: Epidemiology and pathophysiology of Alzheimer's disease. Clin Cornerstone. 2001, 3: 15-26. 10.1016/S1098-3597(01)90045-6.
Article
CAS
PubMed
Google Scholar
Centers for Disease Control and Prevention: Public health and aging: Trends in aging -- United States and worldwide. JAMA. 2003, 289: 1371-1373.
Article
Google Scholar
Ferri CP, Prince M, Brayne C, Brodaty H, et al: Global prevalence of dementia: A Delphi consensus study. Lancet. 2005, 366: 2112-2117.
Article
PubMed Central
PubMed
Google Scholar
Qiu C, De Ronchi D, Fratiglioni L: The epidemiology of the dementias: An update. Curr Opin Psychiatry. 2007, 20: 380-385. 10.1097/YCO.0b013e32816ebc7b.
Article
PubMed
Google Scholar
Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003, 17: 63-67. 10.1097/00002093-200304000-00002.
Article
PubMed
Google Scholar
Lanctot KL, Herrmann N, Yau KK, Khan LR, et al: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ. 2003, 169: 557-564.
PubMed Central
PubMed
Google Scholar
Loveman E, Green C, Kirby J, Takeda A, et al: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006, 10: iii-iv. ix-xi, 1-160
Article
CAS
PubMed
Google Scholar
Masters CL, Beyreuther K: Alzheimer's centennial legacy: Prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006, 129: 2823-2839. 10.1093/brain/awl251.
Article
PubMed
Google Scholar
Becker RE, Greig NH, Giacobini E: Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. J Alzheimers Dis. 2008, 15: 303-325.
PubMed Central
PubMed
Google Scholar
McKhann G, Drachman D, Folstein M, Katzman R, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34: 939-944. 10.1212/WNL.34.7.939.
Article
CAS
PubMed
Google Scholar
Dubois B, Feldman HH, Jacova C, Dekosky ST, et al: Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6: 734-746. 10.1016/S1474-4422(07)70178-3.
Article
PubMed
Google Scholar
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82: 239-259. 10.1007/BF00308809.
Article
CAS
PubMed
Google Scholar
Camicioli R, Fisher N: Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci. 2004, 31: 7-21.
Article
PubMed
Google Scholar
Collerton D, Burn D, McKeith I, O'Brien J: Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord. 2003, 16: 229-237. 10.1159/000072807.
Article
PubMed
Google Scholar
McKeith IG, Dickson DW, Lowe J, Emre M, et al: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology. 2005, 65: 1863-1872. 10.1212/01.wnl.0000187889.17253.b1.
Article
CAS
PubMed
Google Scholar
Samii A, Nutt JG, Ransom BR: Parkinson's disease. Lancet. 2004, 363: 1783-1793. 10.1016/S0140-6736(04)16305-8.
Article
CAS
PubMed
Google Scholar
Emre M: Dementia associated with Parkinson's disease. Lancet Neurol. 2003, 2: 229-237. 10.1016/S1474-4422(03)00351-X.
Article
CAS
PubMed
Google Scholar
Aarsland D, Ballard CG, Halliday G: Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. J Geriatr Psychiatry Neurol. 2004, 17: 137-145. 10.1177/0891988704267470.
Article
PubMed
Google Scholar
Duda JE: Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004, 17 (Suppl 1): 3-14.
Article
CAS
PubMed
Google Scholar
Hansen L, Salmon D, Galasko D, Masliah E, et al: The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology. 1990, 40: 1-8.
Article
CAS
PubMed
Google Scholar
Bartus RT, Dean RL III, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982, 217: 408-414. 10.1126/science.7046051.
Article
CAS
PubMed
Google Scholar
Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry. 1998, 6 (2 Suppl 1): S64-S78.
Article
CAS
PubMed
Google Scholar
Perry EK, Perry RH, Blessed G, Tomlinson BE: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978, 4: 273-277. 10.1111/j.1365-2990.1978.tb00545.x.
Article
CAS
PubMed
Google Scholar
Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, et al: Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000, 54: 407-411. 10.1212/WNL.54.2.407.
Article
CAS
PubMed
Google Scholar
Bullock R, Lane R: Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res. 2007, 4: 277-293.
Article
CAS
PubMed
Google Scholar
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994, 271: 985-991. 10.1001/jama.1994.03510370037029.
Article
CAS
PubMed
Google Scholar
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, et al: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994, 271: 992-998. 10.1001/jama.1994.03510370044030.
Article
CAS
PubMed
Google Scholar
Reisberg B, Doody R, Stoffler A, Schmitt F, et al: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341. 10.1056/NEJMoa013128.
Article
CAS
PubMed
Google Scholar
Greenblatt DJ, Harmatz JS, von Moltke LL, Shader RI: Pharmacokinetics and pharmacodynamics. Psychopharmacology: The Fourth Generation of Progress. Edited by: Bloom FE, Kupfer DJ. 1995, New York, NY, Raven Press, 849-858.
Google Scholar
Rowland M, Tozer TN: Clinical Pharmacokinetics Concepts and Applications. 1995, Philadelphia, PA, Williams & Wilkins, 3
Google Scholar
Kalow W: Pharmacogenetics in biological perspective. Pharmacol Rev. 1997, 49: 369-379.
CAS
PubMed
Google Scholar
Jann MW, Shirley KL, Small GW: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002, 41: 719-739. 10.2165/00003088-200241100-00003.
Article
CAS
PubMed
Google Scholar
Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol. 2003, 2: 539-547. 10.1016/S1474-4422(03)00502-7.
Article
CAS
PubMed
Google Scholar
Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, et al: The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos. 2002, 30: 553-563. 10.1124/dmd.30.5.553.
Article
CAS
PubMed
Google Scholar
Darvesh S, Hopkins DA, Geula C: Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003, 4: 131-138. 10.1038/nrn1035.
Article
CAS
PubMed
Google Scholar
Soreq H, Seidman S: Acetylcholinesterase -- New roles for an old actor. Nat Rev Neurosci. 2001, 2: 294-302.
Article
CAS
PubMed
Google Scholar
Blesa R, Bullock R, He Y, Bergman H, et al: Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006, 16: 771-774. 10.1097/01.fpc.0000220573.05714.ac.
Article
CAS
PubMed
Google Scholar
Touchon J, Bergman H, Bullock R, Rapatz G, et al: Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin. 2006, 22: 49-59. 10.1185/030079906X80279.
Article
CAS
PubMed
Google Scholar
Michaelis ML: Drugs targeting Alzheimer's disease: Some things old and some things new. J Pharmacol Exp Ther. 2003, 304: 897-904.
Article
CAS
PubMed
Google Scholar
Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B: Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002, 18: 129-138. 10.1185/030079902125000471.
Article
CAS
PubMed
Google Scholar
Cacabelos R: Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007, 3: 303-333.
PubMed Central
CAS
PubMed
Google Scholar
Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med. 1999, 341: 1670-1679. 10.1056/NEJM199911253412207.
Article
CAS
PubMed
Google Scholar
Evans WE, McLeod HL: Pharmacogenomics -- Drug disposition, drug targets, and side effects. N Engl J Med. 2003, 348: 538-549. 10.1056/NEJMra020526.
Article
CAS
PubMed
Google Scholar
Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomicsC. Nature. 2007, 429: 464-468.
Article
CAS
Google Scholar
Masellis M, Basile VS, Ozdemir V, Meltzer HY, et al: Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine. Biol Psychiatry. 2000, 47: 252-266. 10.1016/S0006-3223(99)00298-X.
Article
CAS
PubMed
Google Scholar
Kalow W: Atypical plasma cholinesterase. A personal discovery story: A tale of three cities. Can J Anaesth. 2004, 51: 206-211. 10.1007/BF03019096.
Article
PubMed
Google Scholar
Kalow W: Familial incidence of low pseudocholinesterase level. Lancet. 1956, 2: 576-577.
Article
Google Scholar
Lehmann H, Ryan E: The familial incidence of low pseudocholinesterase level. Lancet. 1956, 2: 126-
Google Scholar
Mohs RC, Rosen WG, Davis KL: The Alzheimer's disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983, 19: 448-450.
CAS
PubMed
Google Scholar
Crowe RR: Candidate genes in psychiatry: An epidemiological perspective. Am J Med Genet. 1993, 48: 74-77. 10.1002/ajmg.1320480203.
Article
CAS
PubMed
Google Scholar
Malhotra AK, Goldman D: Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry. 1999, 45: 544-550. 10.1016/S0006-3223(98)00365-5.
Article
CAS
PubMed
Google Scholar
Regalado A: Inventing the pharmacogenomics business. Am J Health Syst Pharm. 1999, 56: 40-50.
CAS
PubMed
Google Scholar
St George-Hyslop PH: Molecular genetics of Alzheimer's disease. Biol Psychiatry. 2000, 47: 183-199. 10.1016/S0006-3223(99)00301-7.
Article
CAS
PubMed
Google Scholar
Shobab LA, Hsiung GY, Feldman HH: Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4: 841-852. 10.1016/S1474-4422(05)70248-9.
Article
CAS
PubMed
Google Scholar
St.George-Hyslop P: Genetics of dementia. Continuum. 2008, 14: 29-48.
Google Scholar
Poirier J, Delisle MC, Quirion R, Aubert I, et al: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 1995, 92: 12260-12264. 10.1073/pnas.92.26.12260.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sjogren M, Hesse C, Basun H, Kol G, et al: Tacrine and rate of progression in Alzheimer's disease -- Relation to ApoE allele genotype. J Neural Transm. 2001, 108: 451-458. 10.1007/s007020170066.
Article
CAS
PubMed
Google Scholar
Farlow MR, Lahiri DK, Poirier J, Davignon J, et al: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998, 50: 669-677. 10.1212/WNL.50.3.669.
Article
CAS
PubMed
Google Scholar
Babic T, Mahovic LD, Sertic J, Petrovecki M, et al: ApoE genotyping and response to galanthamine in Alzheimer's disease -- A real life retrospective study. Coll Antropol. 2004, 28: 199-204.
CAS
PubMed
Google Scholar
Bizzarro A, Marra C, Acciarri A, Valenza A, et al: Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005, 20: 254-261. 10.1159/000087371.
Article
CAS
PubMed
Google Scholar
Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, et al: APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001, 12: 69-77. 10.1159/000051238.
Article
CAS
PubMed
Google Scholar
Almkvist O, Darreh-Shori T, Stefanova E, Spiegel R, et al: Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol. 2004, 11: 253-261. 10.1046/j.1468-1331.2003.00757.x.
Article
CAS
PubMed
Google Scholar
Farlow M, Lane R, Kudaravalli S, He Y: Differential qualitative responses to rivastigmine in APOE epsilon4 carriers and noncarriers. Pharmacogenomics J. 2004, 4: 332-335. 10.1038/sj.tpj.6500267.
Article
CAS
PubMed
Google Scholar
Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, et al: Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol. 2000, 57: 94-99. 10.1001/archneur.57.1.94.
Article
CAS
PubMed
Google Scholar
MacGowan SH, Wilcock GK, Scott M: Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry. 1998, 13: 625-630. 10.1002/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2.
Article
CAS
PubMed
Google Scholar
Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54: 2261-2268. 10.1212/WNL.54.12.2261.
Article
CAS
PubMed
Google Scholar
Rigaud AS, Traykov L, Caputo L, Guelfi MC, et al: The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol. 2000, 7: 255-258. 10.1046/j.1468-1331.2000.00073.x.
Article
CAS
PubMed
Google Scholar
Rigaud AS, Traykov L, Latour F, Couderc R, et al: Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics. 2002, 12: 415-420. 10.1097/00008571-200207000-00009.
Article
CAS
PubMed
Google Scholar
Suh GH, Jung HY, Lee CU, Oh BH, et al: Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006, 21: 33-39. 10.1159/000089217.
Article
CAS
PubMed
Google Scholar
Wallin AK, Hansson O, Blennow K, Londos E, et al: Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. Int J Geriatr Psychiatry. 2009, 24: 638-647. 10.1002/gps.2195.
Article
CAS
PubMed
Google Scholar
Petersen RC, Thomas RG, Grundman M, Bennett D, et al: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005, 352: 2379-2388. 10.1056/NEJMoa050151.
Article
CAS
PubMed
Google Scholar
Feldman HH, Ferris S, Winblad B, Sfikas N, et al: Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurol. 2007, 6: 501-512. 10.1016/S1474-4422(07)70109-6.
Article
CAS
PubMed
Google Scholar
O'Brien KK, Saxby BK, Ballard CG, Grace J, et al: Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics. 2003, 13: 231-239. 10.1097/00008571-200304000-00008.
Article
PubMed
Google Scholar
Bullock R, Touchon J, Bergman H, Gambina G, et al: Rivastigmine and donepezil treatment in moderate to moderatelysevere Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005, 21: 1317-1327. 10.1185/030079905X56565.
Article
CAS
PubMed
Google Scholar
Varsaldi F, Miglio G, Scordo MG, Dahl ML, et al: Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006, 62: 721-726. 10.1007/s00228-006-0168-1.
Article
CAS
PubMed
Google Scholar
Gill SS, Anderson GM, Fischer HD, Bell CM, et al: Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med. 2009, 169: 867-873. 10.1001/archinternmed.2009.43.
Article
PubMed
Google Scholar
Summers WK, Majovski LV, Marsh GM, Tachiki K, et al: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986, 315: 1241-1245. 10.1056/NEJM198611133152001.
Article
CAS
PubMed
Google Scholar
Woolf TF, Pool WF, Bjorge SM, Chang T, et al: Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos. 1993, 21: 874-882.
CAS
PubMed
Google Scholar
Becquemont L, Lecoeur S, Simon T, Beaune P, et al: Glutathione S-transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics. 1997, 7: 251-253. 10.1097/00008571-199706000-00011.
Article
CAS
PubMed
Google Scholar
De Sousa M, Pirmohamed M, Kitteringham NR, Woolf T, et al: No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. Pharmacogenetics. 1998, 8: 353-355.
Article
CAS
PubMed
Google Scholar
Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, et al: Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol. 1995, 39: 411-415. 10.1111/j.1365-2125.1995.tb04470.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Simon T, Becquemont L, Mary-Krause M, de Waziers I, et al: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000, 67: 432-437. 10.1067/mcp.2000.104944.
Article
CAS
PubMed
Google Scholar
Alfirevic A, Mills T, Carr D, Barratt BJ, et al: Tacrine-induced liver damage: An analysis of 19 candidate genes. Pharmacogenet Genomics. 2007, 17: 1091-1100. 10.1097/FPC.0b013e3282f1f12b.
Article
CAS
PubMed
Google Scholar
Carr DF, Alfirevic A, Tugwood JD, Barratt BJ, et al: Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet Genomics. 2007, 17: 961-972. 10.1097/FPC.0b013e3282f00919.
Article
CAS
PubMed
Google Scholar
Behl P, Lanctot KL, Streiner DL, Guimont I, et al: Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: A 1-year observational study in the Sunnybrook dementia cohort. Curr Alzheimer Res. 2006, 3: 147-156. 10.2174/156720506776383031.
Article
CAS
PubMed
Google Scholar
Chertkow H, Black S: Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci. 2007, 34 (Suppl 1): S77-S83.
Article
PubMed
Google Scholar
Hariri AR, Weinberger DR: Imaging genomics. Br Med Bull. 2003, 65: 259-270. 10.1093/bmb/65.1.259.
Article
CAS
PubMed
Google Scholar
Thal LJ, Kantarci K, Reiman EM, Klunk WE, et al: The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006, 20: 6-15. 10.1097/01.wad.0000191420.61260.a8.
Article
PubMed Central
PubMed
Google Scholar
Leboyer M, Bellivier F, Nosten-Bertrand M, Jouvent R, et al: Psychiatric genetics: Search for phenotypes. Trends Neurosci. 1998, 21: 102-105. 10.1016/S0166-2236(97)01187-9.
Article
CAS
PubMed
Google Scholar
Bennett DA, De Jager PL, Leurgans SE, Schneider JA: Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009, 72: 1495-1503. 10.1212/WNL.0b013e3181a2e87d.
Article
PubMed Central
PubMed
Google Scholar
Darreh-Shori T, Kadir A, Almkvist O, Grut M, et al: Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging. 2008, 29: 168-184. 10.1016/j.neurobiolaging.2006.09.020.
Article
CAS
PubMed
Google Scholar
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, et al: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-413. 10.1002/ana.21610.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kesslak JP, Nalcioglu O, Cotman CW: Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology. 1991, 41: 51-54. 10.1212/WNL.41.1.51.
Article
CAS
PubMed
Google Scholar
Jack CR, Petersen RC, Xu YC, O'Brien PC, et al: Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol. 1998, 43: 303-310. 10.1002/ana.410430307.
Article
PubMed Central
PubMed
Google Scholar
Mori S: Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci. 2002, 977: 493-500. 10.1111/j.1749-6632.2002.tb04856.x.
Article
CAS
PubMed
Google Scholar
Schuff N, Woerner N, Boreta L, Kornfield T, et al: MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009, 132: 1067-1077.
Article
PubMed Central
CAS
PubMed
Google Scholar
van de Pol LA, van der Flier WM, Korf ES, Fox NC: Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology. 2007, 69: 1491-1497. 10.1212/01.wnl.0000277458.26846.96.
Article
CAS
PubMed
Google Scholar
Lane R, Feldman HH, Meyer J, He Y, et al: Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics. 2008, 18: 289-298. 10.1097/FPC.0b013e3282f63f29.
Article
CAS
PubMed
Google Scholar
Hashimoto M, Kazui H, Matsumoto K, Nakano Y, et al: Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychiatry. 2005, 62: 676-682.
Article
Google Scholar
Jack CR, Petersen RC, Grundman M, Jin S, et al: Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008, 29: 1285-1295. 10.1016/j.neurobiolaging.2007.03.004.
Article
PubMed Central
CAS
PubMed
Google Scholar
Swartz RH, Sahlas DJ, Black SE: Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter?. J Stroke Cerebrovasc Dis. 2003, 12 (1): 29-36. 10.1053/jscd.2003.5.
Article
PubMed
Google Scholar
Bocti C, Swartz RH, Gao FQ, Sahlas DJ, et al: A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke. 2005, 36: 2126-2131. 10.1161/01.STR.0000183615.07936.b6.
Article
PubMed
Google Scholar
Behl P, Bocti C, Swartz RH, Gao F, et al: Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol. 2007, 64: 266-272. 10.1001/archneur.64.2.266.
Article
PubMed
Google Scholar
Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, et al: In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999, 52: 691-699. 10.1212/WNL.52.4.691.
Article
CAS
PubMed
Google Scholar
Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, et al: Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology. 2001, 56: 408-410. 10.1212/WNL.56.3.408.
Article
CAS
PubMed
Google Scholar
Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, et al: Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006, 253: 242-247. 10.1007/s00415-005-0971-0.
Article
CAS
PubMed
Google Scholar
Mega MS, Cummings JL, O'Connor SM, Dinov ID, et al: Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001, 14: 63-68.
CAS
PubMed
Google Scholar
Potkin SG, Anand R, Fleming K, Alva G, et al: Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol. 2001, 4: 223-230.
Article
CAS
PubMed
Google Scholar
Venneri A, Shanks MF, Staff RT, Pestell SJ, et al: Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport. 2002, 13: 83-87. 10.1097/00001756-200201210-00020.
Article
CAS
PubMed
Google Scholar
Nakano S, Asada T, Matsuda H, Uno M, et al: Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med. 2001, 42: 1441-1445.
CAS
PubMed
Google Scholar
Nobili F, Koulibaly M, Vitali P, Migneco O, et al: Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002, 43: 983-990.
CAS
PubMed
Google Scholar
Nobili F, Vitali P, Canfora M, Girtler N, et al: Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol. 2002, 113: 1241-1248. 10.1016/S1388-2457(02)00110-4.
Article
CAS
PubMed
Google Scholar
Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, et al: The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci. 2003, 216: 119-126. 10.1016/S0022-510X(03)00229-6.
Article
CAS
PubMed
Google Scholar
Ceravolo R, Volterrani D, Tognoni G, Dell'Agnello G, et al: Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol. 2004, 27: 166-170. 10.1097/01.wnf.0000138636.42121.45.
Article
CAS
PubMed
Google Scholar
Tanaka M, Namiki C, Thuy DH, Yoshida H, et al: Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J Neurol Sci. 2004, 225: 135-141. 10.1016/j.jns.2004.07.009.
Article
CAS
PubMed
Google Scholar
Imamura K, Wada-Isoe K, Kowa H, Tanabe Y, et al: The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. Neurocase. 2008, 14: 271-275. 10.1080/13554790802269984.
Article
PubMed
Google Scholar
Mori E, Lee K, Yasuda M, Hashimoto M, et al: Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol. 2002, 51: 209-214. 10.1002/ana.10093.
Article
CAS
PubMed
Google Scholar
O'Brien JT, Firbank MJ, Mosimann UP, Burn DJ, et al: Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res. 2005, 139: 79-88. 10.1016/j.pscychresns.2005.04.002.
Article
PubMed
Google Scholar
Mori T, Ikeda M, Fukuhara R, Nestor PJ, et al: Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology. 2006, 66: 935-937. 10.1212/01.wnl.0000203114.03976.b0.
Article
CAS
PubMed
Google Scholar
Ceravolo R, Volterrani D, Frosini D, Bernardini S, et al: Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm. 2006, 113: 1787-1790. 10.1007/s00702-006-0478-6.
Article
CAS
PubMed
Google Scholar
Colloby S, O'Brien J: Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004, 17: 158-163. 10.1177/0891988704267468.
Article
PubMed
Google Scholar
Roses AD: The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology. 2009, 34: 6-17. 10.1038/npp.2008.153.
Article
CAS
PubMed
Google Scholar